Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Zoom Technologies to Enter China New Media Arena Through Leimone Culture Deal With China Central Television
Mar 24, 2010 08:32 ET
http://www.marketwire.com/press-release/Zoom-Technologies-Enter-China-New-Media-Arena-Through-Leimone-Culture-Deal-With-China-NASDAQ-ZOOM-1137037.htm
Leimone Culture and CCTV Sign the First Official CCTV Contract for Mobile Media Services
BEIJING--(Marketwire - March 24, 2010) - Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China-based manufacturer of mobile phones and other mobile electronic products, today announced that the Company's previously disclosed acquisition target, Beijing Leimone Shengtong Culture Development Company (Leimone Culture), has signed an agreement with China Central Television (CCTV), the major state television broadcaster in China, with 19 channels broadcasting to more than one billion viewers. According to the agreement, Leimone Culture will provide approved media content to CCTV's mobile users and will bundle CCTV.com's mobile TV access link onto Zoom's branded "Leimone" mobile phones and onto Zoom Original Equipment Manufacturer (OEM) customers' phones.
Pursuant to Section 1.3 of the Share Exchange Agreement dated January 28, 2009 between Zoom, Gold Lion Holding Ltd and Mr. Lei Gu, which shareholders of Zoom approved on September 8, 2009, Zoom has the option of purchasing Mr. Gu's shares of a list of companies controlled by him, and among these companies is Leimone Culture of which Mr. Gu owned 70% in September 2009. On December 1, 2009, Zoom's board of directors approved to pursue the acquisition of 100% of Leimone Culture subject to further due diligence, with details of the transaction to be finalized in the first half of 2010.
Mr. Leo Gu, Chairman and CEO of Zoom Technologies, commented, "This agreement with CCTV is the first of its kind for mobile media services, and is a milestone for Leimone Culture and Zoom Technologies. It partners Zoom through Leimone Culture with the largest media company in China, and positions us to benefit from the outstanding growth expected in the business of delivering video programs to mobile phones. We expect our mobile media business to grow significantly once Zoom completes the acquisition of Leimone Culture later this year. China's continuing economic growth and the strength of our manufacturing business also give us confidence in achieving significant growth."
CCTV currently captures 60% of China's mobile media services, making CCTV the largest program provider of "new media" for the mobile handset. Leimone Culture is the first company officially contracted by CCTV to participate with CCTV in this new mobile media service. Leimone Culture will generate revenue based on viewership of media programs supplied by Leimone Culture onto CCTV's mobile TV program access link. Leimone Culture has been selected as CCTV's supplier for a number of reasons, including content quality and Zoom's manufacturing capabilities, which can bundle the CCTV mobile TV access link in up to 10 million mobile phones in 2010.
Zoom expects to finalize the acquisition of Leimone Culture by mid-year 2010.
Leimone Culture has been a provider of mobile video services to China's top tier mobile phone service providers, including China Mobile since 2005 and China Unicom since 2007. Since the advent of 3G in China in mid-2009, Leimone Culture has captured revenues from advertisements loaded onto new phones, value-added applications provided to the mobile operators, the production of mobile short films, and web-based ad sales.
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
Forward-Looking Statements
Certain statements in this press release may constitute "forward looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events, including the acquisition of Leimone, which may require shareholder approval which cannot be assured. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Perifosine ...
http://www.cnxmarketlink.com/en/releases/archive/March2010/24/c4373.html
AEterna Zentaris Reports Fourth Quarter and Full-Year 2009 Financial and Operating Results
All amounts are in U.S. dollars
QUEBEC CITY, March 24 /CNW Telbec/ - AEterna Zentaris Inc. (NASDAQ: AEZS,
TSX: AEZ) (the "Company"), a late-stage drug development company specialized
in oncology and endocrine therapy, today reported financial and operating
results as at and for the fourth quarter and the full year ended December 31,
2009.
<<
2009 Highlights
Perifosine
- Updated positive Phase 2 efficacy and safety data as well as new
survival data for perifosine in combination therapy for
relapsed/refractory multiple myeloma, were presented at the American
Society of Hematology's ("ASH") annual meeting. Results showed that the
overall response rate was 41% and median overall survival was reported
at 25 months for all evaluable patients. The combination therapy
maintained an acceptable safety profile and no unexpected adverse
events were reported.
- Positive Phase 2 data on perifosine in advanced metastatic colon cancer
and in advanced renal cell carcinoma were presented at the American
Society of Clinical Oncology's ("ASCO") annual meeting. The data
demonstrated perifosine's anti-cancer activity and efficacy both as a
single agent and in combination therapy. Data at ASCO and ASH meetings
were generated by the Company's North American partner, Keryx
Biopharmaceuticals ("Keryx").
- A Phase 3 registration trial with perifosine in relapsed/refractory
multiple myeloma was initiated under a Special Protocol Assessment
("SPA"). Perifosine was also granted Orphan Drug and Fast Track
designations by the Food and Drug Administration ("FDA") in this same
indication. The trial is being conducted by Keryx.
AEZS-108
- Positive Phase 2 preliminary results with AEZS-108 in platinum-
resistant and taxane-pretreated ovarian cancer were disclosed, which
showed that the study met its primary efficacy endpoint of 5 or more
responders in 41 evaluable patients.
- Positive Phase 2 preliminary results with AEZS-108 in advanced or
recurrent endometrial cancer were disclosed. The study met its pre-
defined primary efficacy endpoint of 5 or more responder patients. The
trial in endometrial and ovarian cancer was conducted in collaboration
with the German oncology study cooperative group, Arbeitsgemeinschaft
Gynackologisehe Onkologie ("AGO"). Data for both indications were
presented at the American Association for Cancer Research's ("AACR")
annual meeting.
AEZS-112
- Phase 1 results with AEZS-112 in advanced solid tumors or lymphoma were
disclosed, showing prolonged courses of stable disease, excellent
tolerability and potential for long-term use as a combination treatment
for cancer.
AEZS-130
- A Poster was presented at the Endocrine Society's ("ENDO") annual
meeting, on AEZS-130 (Solorel(TM)), reporting the first clinical data
relating to its use as a simple oral diagnostic test for adult Growth
Hormone Deficiency (GHD).
Cetrorelix
- A licensing agreement with sanofi-aventis U.S. ("sanofi-aventis") for
the development, registration and marketing of cetrorelix in benign
prostatic hyperplasia ("BPH") for the U.S. market was signed. The
agreement provided AEterna Zentaris with a $30 million gross upfront
payment.
- Results of two Phase 3 efficacy studies with cetrorelix in BPH which
did not achieve their primary endpoint were disclosed.
- The Company's licensing agreement with sanofi-aventis for cetrorelix in
BPH, subsequent to the aforementioned Phase 3 results, was terminated.
Corporate Developments
- The Company completed two registered direct offerings of common shares
and warrants to certain U.S. institutional investors, for combined
gross proceeds of $15.5 million.
Subsequent to Year-End
- A statistically significant benefit in survival from updated results of
a Phase 2 study of perifosine in advanced metastatic colon cancer was
reported by Keryx.
- A publication in the February 2010 issue of the Journal of Clinical
Cancer Research reported positive Phase 2 results for perifosine as a
single agent for the treatment of advanced Waldenstrom's
macroglobulinemia.
- The FDA granted a SPA for the Phase 3 trial of perifosine in
combination therapy for refractory metastatic colorectal cancer. The
trial is to be conducted by Keryx.
- The Committee for Orphan Medicinal Products of the European Medicines
Agency issued a positive opinion to AEterna Zentaris for orphan
medicinal product designation for perifosine in multiple myeloma.
>>
...
NOVAVAX Announces Positive Clinical Results from First Stage of Pivotal Study of 2009 A/H1N1 VLP Pandemic Influenza Vaccine in Mexico
Date : 03/24/2010 @ 8:00AM
Source : PR Newswire
Stock : Novavax (NVAX)
http://ih.advfn.com/p.php?pid=nmona&cb=1269432271&article=42102285&symbol=N^NVAX
-- Independent Data Safety Monitoring Board (DSMB) concludes that Novavax's 2009 H1N1 VLP pandemic influenza vaccine is well-tolerated and induces robust immune responses with a single injection at all dose levels tested
-- Stage B enrollment completed with over 3,500 volunteers in the trial
PR Newswire
ROCKVILLE, Md., March 24
ROCKVILLE, Md., March 24 /PRNewswire-FirstCall/ --
Novavax, Inc. (Nasdaq: NVAX) announced today positive results from the entire 1,000 subject Stage A of its two-stage pivotal study evaluating the safety and immunogenicity of Novavax's unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine. The data showed that safety and immunogenicity of the vaccine were consistent with preliminary results disclosed earlier from the first 500 volunteers of Stage A where the vaccine was found to be well tolerated and immunogenic at all three dose levels tested. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries. The study is being conducted at the Mexican Institute of Social Security (IMSS), which is the largest medical and research center in Latin America.
The Stage A part of the pivotal trial is a randomized, double-blind, placebo-controlled study in which 1,000 healthy volunteers aged 18 to 64 years old were evaluated to determine the safety, tolerability and immunogenicity of the vaccine. All volunteers were vaccinated with two doses of either 5 mcg, 15 mcg or 45 mcg of Novavax's 2009 A/H1N1 VLP pandemic influenza vaccine or a placebo. The DSMB reviewed the safety and immunogenicity data from 1,000 healthy volunteers. Serological results from the 1,000 subjects 14 days after the first injection of Novavax's 2009 A/H1N1 VLP pandemic influenza vaccine showed that the vaccine at all three dose levels of 5 mcg, 15 mcg or 45 mcg induced robust immune responses that are considered protective. The vaccine was well tolerated at all three dose levels and exhibited no systemic side effects and mostly mild local site reactions, similar to placebo. These data confirmed that a single dose of 15 mcg was optimal to induce robust immune responses in broader age populations with a highly satisfactory safety profile.
"The success of Novavax's 2009 H1N1 VLP pandemic influenza vaccine in the Mexico pivotal study clearly demonstrates the desirable tolerability and immunogenicity profile of our vaccine candidate in the largest clinical trial conducted by the Company to date. We are highly encouraged by these results as the data meet the immunogenicity criteria of both the United States and European regulatory authorities. These data enable potential emergency use of the vaccine in pandemic situations and could be supportive in other countries in addition to Mexico. Based on these positive data, we have filed for regulatory approval of our H1N1 VLP pandemic influenza vaccine candidate in Mexico," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "The substantial safety dataset and strong immunogenicity signal from this large study provide us confidence as we plan Phase III studies of our seasonal trivalent influenza VLP vaccine, pending results from the ongoing Phase IIa trial in older volunteers and discussions with the U.S. Food and Drug Administration (FDA)."
Earlier this month, Novavax completed enrollment of a cohort of over 3,500 volunteers in Stage B of this pivotal study. Over 2,500 of these volunteers received a single 15 mcg injection of Novavax's unadjuvanted 2009 A/H1N1 VLP pandemic influenza vaccine while 1,000 of the volunteers received a placebo. The purpose of Stage B portion of this clinical study was to evaluate safety of the VLP vaccine.
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
Forward-Looking Statements
Statements herein relating to clinical trials and development of the 2009 H1N1 and seasonal vaccines, the potential use of any data from clinical trials in Mexico and other countries, including the U.S., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially include full and complete clinical trial results, which may not be sufficient for regulatory approval in Mexico or may indicate safety concerns not yet encountered; even if the results reported today or other final and complete results of the clinical trial are positive, the data may not be accepted by regulatory bodies in the U.S. or other countries; the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; even if approved by the Mexican government, sales of the 2009 H1N1 vaccine may be poor because there is currently an over supply of H1N1 vaccine; our vaccines have not been manufactured at commercial levels and unanticipated costs and delays during the scale-up process could occur; the 2009 H1N1 vaccine must be manufactured quickly, or it may not be available for sale in Mexico until after the 2009/2010 influenza season has ended even if approved; our ability to progress the seasonal product into Phase III clinical studies; and the scope, initiation, rate and progress of such Phase III or any other clinical study. Further information on risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.
SOURCE Novavax, Inc.
NOVAVAX Announces Positive Clinical Results from First Stage of Pivotal Study of 2009 A/H1N1 VLP Pandemic Influenza Vaccine in Mexico
Date : 03/24/2010 @ 8:00AM
Source : PR Newswire
Stock : Novavax (NVAX)
http://ih.advfn.com/p.php?pid=nmona&cb=1269432271&article=42102285&symbol=N^NVAX
-- Independent Data Safety Monitoring Board (DSMB) concludes that Novavax's 2009 H1N1 VLP pandemic influenza vaccine is well-tolerated and induces robust immune responses with a single injection at all dose levels tested
-- Stage B enrollment completed with over 3,500 volunteers in the trial
PR Newswire
ROCKVILLE, Md., March 24
ROCKVILLE, Md., March 24 /PRNewswire-FirstCall/ --
Novavax, Inc. (Nasdaq: NVAX) announced today positive results from the entire 1,000 subject Stage A of its two-stage pivotal study evaluating the safety and immunogenicity of Novavax's unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine. The data showed that safety and immunogenicity of the vaccine were consistent with preliminary results disclosed earlier from the first 500 volunteers of Stage A where the vaccine was found to be well tolerated and immunogenic at all three dose levels tested. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries. The study is being conducted at the Mexican Institute of Social Security (IMSS), which is the largest medical and research center in Latin America.
The Stage A part of the pivotal trial is a randomized, double-blind, placebo-controlled study in which 1,000 healthy volunteers aged 18 to 64 years old were evaluated to determine the safety, tolerability and immunogenicity of the vaccine. All volunteers were vaccinated with two doses of either 5 mcg, 15 mcg or 45 mcg of Novavax's 2009 A/H1N1 VLP pandemic influenza vaccine or a placebo. The DSMB reviewed the safety and immunogenicity data from 1,000 healthy volunteers. Serological results from the 1,000 subjects 14 days after the first injection of Novavax's 2009 A/H1N1 VLP pandemic influenza vaccine showed that the vaccine at all three dose levels of 5 mcg, 15 mcg or 45 mcg induced robust immune responses that are considered protective. The vaccine was well tolerated at all three dose levels and exhibited no systemic side effects and mostly mild local site reactions, similar to placebo. These data confirmed that a single dose of 15 mcg was optimal to induce robust immune responses in broader age populations with a highly satisfactory safety profile.
"The success of Novavax's 2009 H1N1 VLP pandemic influenza vaccine in the Mexico pivotal study clearly demonstrates the desirable tolerability and immunogenicity profile of our vaccine candidate in the largest clinical trial conducted by the Company to date. We are highly encouraged by these results as the data meet the immunogenicity criteria of both the United States and European regulatory authorities. These data enable potential emergency use of the vaccine in pandemic situations and could be supportive in other countries in addition to Mexico. Based on these positive data, we have filed for regulatory approval of our H1N1 VLP pandemic influenza vaccine candidate in Mexico," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "The substantial safety dataset and strong immunogenicity signal from this large study provide us confidence as we plan Phase III studies of our seasonal trivalent influenza VLP vaccine, pending results from the ongoing Phase IIa trial in older volunteers and discussions with the U.S. Food and Drug Administration (FDA)."
Earlier this month, Novavax completed enrollment of a cohort of over 3,500 volunteers in Stage B of this pivotal study. Over 2,500 of these volunteers received a single 15 mcg injection of Novavax's unadjuvanted 2009 A/H1N1 VLP pandemic influenza vaccine while 1,000 of the volunteers received a placebo. The purpose of Stage B portion of this clinical study was to evaluate safety of the VLP vaccine.
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
Forward-Looking Statements
Statements herein relating to clinical trials and development of the 2009 H1N1 and seasonal vaccines, the potential use of any data from clinical trials in Mexico and other countries, including the U.S., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially include full and complete clinical trial results, which may not be sufficient for regulatory approval in Mexico or may indicate safety concerns not yet encountered; even if the results reported today or other final and complete results of the clinical trial are positive, the data may not be accepted by regulatory bodies in the U.S. or other countries; the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; even if approved by the Mexican government, sales of the 2009 H1N1 vaccine may be poor because there is currently an over supply of H1N1 vaccine; our vaccines have not been manufactured at commercial levels and unanticipated costs and delays during the scale-up process could occur; the 2009 H1N1 vaccine must be manufactured quickly, or it may not be available for sale in Mexico until after the 2009/2010 influenza season has ended even if approved; our ability to progress the seasonal product into Phase III clinical studies; and the scope, initiation, rate and progress of such Phase III or any other clinical study. Further information on risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.
SOURCE Novavax, Inc.
HARTFORD FINANCIAL SERVICES GROUP INC/DE Financials
EDGAR Online Financials(Tue 1:04pm)
http://finance.yahoo.com/q/is?s=hig
Unilife Reports Fiscal 2010 Second Quarter Financial Results
Date : 03/23/2010 @ 4:05PM
Source : PR Newswire
Stock : Unilife (MM) (UNIS)
http://ih.advfn.com/p.php?pid=nmona&cb=1269376597&article=42092856&symbol=N^UNIS
PR Newswire
LEWISBERRY, Pa., March 23
LEWISBERRY, Pa., March 23 /PRNewswire-FirstCall/ --
Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced financial results for its fiscal 2010 second quarter and six months ended December 31, 2009.
Recent Company Highlights:
Successfully redomiciled to the U.S. and listed on the NASDAQ Global MarketAgreed to a list of therapeutic drug classes with sanofi-aventis for Unifill™ syringesStarted commercial manufacturing of Unitract™ 1mL safety syringesDonated first shipment of Unitract™ 1mL safety syringes to the Haiti relief effortSigned exclusive five-year agreement with Stason Pharmaceuticals including annual minimum orders for the Unitract™ 1mL syringe in Japan, China and Taiwan Completed an equity raise of $47.1 million in November 2009 "Unilife continues to meet or exceed its key business milestones," stated Alan Shortall, CEO of Unilife. "The redomiciliation of Unilife to the United States and our listing on the NASDAQ Global Market has been a significant achievement. This move reflects our position as a US based emerging global leader for innovative safety medical devices, and allows Unilife to attract additional world class team members that will support the continued expansion of our business activities, product lines and industrial capabilities.
"I am pleased to say that we have begun to introduce our safety syringe technology into the market, with the initial shipment of Unitract™ 1mL safety syringes into Haiti to support humanitarian relief efforts. Stason Pharmaceuticals has also signed an exclusive five-year distribution agreement with us for the sale of the Unitract™ 1mL safety syringe within Japan, Taiwan and China. In addition to supporting regulatory approval and business development activities within Asia, Stason Pharmaceuticals has committed to immediately placing an initial commercial order for one million units of the Unitract™ 1mL safety syringe. Our Unitract™ 1mL syringes will continue to be rolled out across target international markets during the next twelve months.
"Construction of our new manufacturing plant in York, Pennsylvania is progressing according to schedule with the external walls and roof of the main section of the building now in place. This 165,000sf, state of the art facility is scheduled to be completed in late 2010, so that we will be in a position to commence the supply of our Unifill™ safety syringes to pharmaceutical customers in early 2011. This timeline puts us more than a year ahead of our original schedule for the industrialization program for the Unifill™ syringe.
"In addition, we have agreed to a list of therapeutic drug classes including antithrombotic agents and vaccines within which sanofi-aventis has the exclusive right to purchase the Unifill™ syringe. We may now commence formal discussions with other pharmaceutical companies relating to the potential use of the Unifill™ syringe within a number of significant therapeutic classes that fall outside of areas retained by sanofi-aventis," Mr. Shortall said.
Financial Results for Three and Six Months Ended December 31, 2009 and 2008
Net revenues for the three months ended December 31, 2009 were $3.2 million, compared to $5.8 million for the same period in 2008. The Company's net loss for the three months ended December 31, 2009 was $(5.9) million, or $(0.13) per diluted share, as compared to a net loss of $(861,000), or $(0.03) per diluted share, for the same period in 2008. Adjusted net loss for the three months ended December 31, 2009, which excludes approximately $2.7 million in share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $(3.2) million, or $(0.07) per diluted share.
Net revenues for the six months ended December 31, 2009 were $6.4 million, compared to $8.1 million for the same period in 2008. The Company's net loss for the six months ended December 31, 2009 was $(8.0) million, or $(0.19) per diluted share, as compared to a net loss of $(2.5) million, or $(0.07) per diluted share, for the same period in 2008. Adjusted net loss for the six months ended December 31, 2009, which excludes approximately $4.0 million in share-based compensation expense, depreciation and amortization and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $(4.0) million, or $(0.10) per diluted share.
As of December 31, 2009, the Company's cash and cash equivalents were $41.4 million.
Future Company Milestones – Calendar 2010:
Continued global rollout of Unitract™ 1mL SyringesCompletion of new headquarters and production facility Installation of Unifill™ assembly line (60 million units a year)Completion of Unifill™ industrialization programAgreements with additional pharmaceutical companiesConference Call Information
Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Daylight Time on March 23, 2010, to review the Company's financial results, market trends, and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator controlled needle retraction features which are fully-integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Non-GAAP Financial Measures
U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide a reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with our redomiciliation and Nasdaq listing.
Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached tables.
General: UNIS-G
Investor Contacts (US):
Investor Contacts (Australia):
Todd Fromer / Garth Russell
Stuart Fine
Jeff Carter
KCSA Strategic Communications
Carpe DM Inc
Unilife Corporation
P: + 1 212-682-6300
P: + 1 908-469-1788
P: + 61 2 8346 6500
(Tables Below)
UNILIFE CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
December 31, June 30,
2009 2009
------------- ---------
Assets
Current Assets:
Cash and cash equivalents $41,354 $3,627
Accounts receivable 2,376 7,333
Inventories 1,398 1,097
Prepaid expenses and other current assets 538 223
------ ------
Total current assets 45,666 12,280
Property, plant and equipment, net 15,936 9,137
Goodwill 11,235 10,235
Intangible assets, net 45 43
Other assets 196 517
------- -------
Total assets $73,078 $32,212
======= =======
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable $1,454 $1,103
Accrued expenses 908 6,097
Current portion of long-term debt 405 405
Deferred revenue 2,932 2,642
----- -----
Total current liabilities 5,699 10,247
Long-term debt, less current portion 2,499 2,728
Deferred revenue 7,330 7,926
----- -----
Total liabilities 15,528 20,901
------ ------
Commitments and contingencies
Stockholders' Equity:
Preferred stock, $0.01 par value,
50,000,000 shares authorized as of
December 31, 2009; none issued or
outstanding as of December 31, 2009
and June 30, 2009 - -
Common stock, $0.01 par value,
250,000,000 shares authorized as
of December 31, 2009; 51,784,437
and 36,625,802 shares issued and
outstanding as of December 31,
2009 and June 30, 2009, respectively 518 366
Additional paid-in-capital 113,430 57,987
Accumulated deficit (57,881) (49,902)
Accumulated other comprehensive income 1,483 2,860
----- -----
Total stockholders' equity 57,550 11,311
------ ------
Total liabilities and
stockholders' equity $73,078 $32,212
======= =======
UNILIFE CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
December 31, December 31,
------------- -------------
2009 2008 2009 2008
---- ---- ---- ----
Revenues $3,245 $5,822 $6,353 $8,127
Cost of sales 707 1,042 1,572 2,173
--- ----- ----- -----
Gross profit 2,538 4,780 4,781 5,954
----- ----- ----- -----
Operating expenses:
Research & development 287 216 686 347
Selling, general
and administrative 7,517 5,241 11,259 7,663
Depreciation and
amortization 776 155 1,031 299
--- --- ----- ---
Total operating expenses 8,580 5,612 12,976 8,309
----- ----- ------ -----
Operating loss (6,042) (832) (8,195) (2,355)
Interest expense 14 106 61 231
Interest income (252) (165) (257) (285)
Other (income)expense, net 111 88 (20) 176
--- --- --- ---
Net loss $(5,915) $(861) $(7,979) $(2,477)
======== ====== ======== ========
Loss per share:
Basic loss per share $(0.13) $(0.03) $(0.19) $(0.07)
======= ======= ======= =======
Diluted loss per share $(0.13) $(0.03) $(0.19) $(0.07)
======= ======= ======= =======
UNILIFE CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Measure
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
December 31, December 31,
------------ ------------
2009 2008 2009 2008
---- ---- ---- ----
Net loss $(5,915) $(861) $(7,979) $(2,477)
Share-based
compensation expense 201 2,205 771 2,298
Depreciation and
amortization 776 155 1,031 299
Interest expense 14 106 61 231
Non-recurring costs
associated with
redomiciliation & US
listing* 1,710 - 2,135 -
----- --- ----- ---
Adjusted net income
(loss) $(3,214) $1,605 $(3,981) $351
======== ====== ======== ====
Adjusted net income
(loss) per share –
diluted $(0.07) $0.05 $(0.10) $0.01
======= ===== ======= =====
* Includes legal, consulting and other professional fees incurred in
connection with the Company's redomiciliation to the United States
and Nasdaq listing.
SOURCE Unilife Corporation
Keryx Biopharmaceuticals, Inc. To Hold Conference Call on Fourth Quarter and Year-End 2009 Financial Results on Thursday, March 25, 2010 at 8:30 a.m. EDT
Date : 03/23/2010 @ 4:30PM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&cb=1269376456&article=42093253&symbol=N^KERX
Keryx Biopharmaceuticals, Inc. To Hold Conference Call on Fourth Quarter and Year-End 2009 Financial Results on Thursday, March 25, 2010 at 8:30 a.m. EDT
PR Newswire
NEW YORK, March 23
NEW YORK, March 23 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Thursday, March 25, 2010 at 8:30 a.m. EDT to discuss the fourth quarter and year end 2009 financial results and outlook for 2010. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.
In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
The press release announcing the Company's financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment, or SPA, in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director, Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5962
SOURCE Keryx Biopharmaceuticals, Inc.
Hartford Financial Services Group "equal weight," target price raised
http://www.newratings.com/en/main/company_headline.m?id=2039555
12:30p.m. - Barclays Capital
NEW YORK, March 23 (newratings.com) - Analysts at Barclays Capital reiterate their "equal weight" rating on Hartford Financial Services Group Inc (HIG). The target price has been raised from $19 to $31.
NexMed, Inc. Enters into Distribution Agreement for Japan
Date : 03/23/2010 @ 1:21PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269365105&article=42090279&symbol=N^NEXM
NexMed, Inc. (Nasdaq: NEXM), a company with a revenue generating discovery pre-clinical CRO and a pipeline of products based on the NexACT® technology, today announced that its wholly-owned subsidiary, Bio-Quant has signed a distribution agreement with Cosmo Bio Co., Ltd, under which Cosmo Bio will market Bio-Quant’s discovery and pre-clinical contract research services throughout Japan.
Based in Tokyo, Cosmo Bio is a well established distributor of life sciences products and services to academic researchers, biotechnology and pharmaceutical companies, specializing in oncology, inflammation, immunology and metabolic diseases.
Bassam Damaj, Ph.D., Chief Executive Officer of NexMed, stated, “With the third largest concentration of biotechnology and pharmaceutical companies in the world behind the U.S. and Europe, Japan represents a key growth opportunity for Bio-Quant. As such, we are very pleased to have solidified this partnership with Cosmo Bio. The distribution agreement provides us with a formal presence in Japan, where we have already established an initial foothold with a number of leading Japanese pharmaceutical companies. We look forward to working with the Cosmo Bio team as we further build our customer base, streamline incoming requests and provide centralized customer support.”
About NexMed
Based in San Diego, California, NexMed’s goal is to generate revenues from the growth of its discovery pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.
For further information, go to www.nexmed.com and www.bio-quant.com.
Forward Looking Statement
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will be able to implement its growth strategy.
NexMed, Inc. Enters into Distribution Agreement for Japan
Date : 03/23/2010 @ 1:21PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269365105&article=42090279&symbol=N^NEXM
Obama signs historic $938 billion health overhaul
Obama signs historic $938 billion health overhaul, setting stage for November elections
Darlene Superville, Associated Press Writer,
On Tuesday March 23, 2010, 11:56 am
http://finance.yahoo.com/news/Obama-to-sign-health-bill-apf-4220371251.html;_ylt=AmBnhEnvir2AefqnaGcNT3O7YWsA;_ylu=X3oDMTE1dW9scTVrBHBvcwMyBHNlYwN0b3BTdG9yaWVzBHNsawNvYmFtYXNpZ25zaGk-?x=0&sec=topStories&pos=main&asset=&ccode=
WASHINGTON (AP) -- A broadly smiling President Barack Obama on Tuesday signed a historic $938 billion health care overhaul that guarantees coverage for 32 million uninsured Americans and will touch nearly every citizen's life, presiding over the biggest shift in U.S. domestic policy since the 1960s and capping a divisive, yearlong debate that could define the November elections.
Celebrating "a new season in America" -- the biggest accomplishment of his White House and one denied to a line of presidents before him -- Obama made the massive bill law with an East Room signing ceremony. He was joined by jubilant House and Senate Democrats as well as lesser-known people whose health care struggles have touched the president. Obama scheduled back-to-back events to mark the moment, with much of his White House audience, as well as hundreds of others, heading to the Interior Department immediately after the signing.
"Today after almost a century of trial, today after over a year of debate, today after all the votes have been tallied, health insurance reform becomes law in the United States of America. Today," Obama said, interrupted by applause after nearly every sentence. "All of the overheated rhetoric over reform will finally confront the reality of reform."
THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP's earlier story is below.
WASHINGTON (AP) -- President Barack Obama has signed the $938 billion health care overhaul that guarantees coverage for 32 million uninsured Americans and represents the biggest accomplishment of his presidency.
The new law will be the main issue in this fall's midterm elections. Obama signed the bill at an elaborate ceremony Tuesday in the East Room of the White House, to be followed by an even larger celebration at an Interior Department auditorium.
ProLogis to Host First Quarter 2010 Financial Results Webcast and Conference Call
Date : 03/22/2010 @ 5:15PM
Source : PR Newswire
Stock : Prologis (PLD)
http://ih.advfn.com/p.php?pid=nmona&article=42074824&symbol=PLD
ProLogis to Host First Quarter 2010 Financial Results Webcast and Conference Call
PR Newswire
DENVER, March 22
DENVER, March 22 /PRNewswire-FirstCall/ --
ProLogis (NYSE: PLD), a leading global provider of distribution facilities, will host its First Quarter 2010 Financial Results Webcast and Conference Call with senior management to discuss quarterly results, current market conditions and future outlook on Thursday, April 22, 2010, at 10:00 a.m. Eastern Time.
Earnings Release
ProLogis' first quarter 2010 financial results will be released on Thursday, April 22, 2010, before market open and will be available on the ProLogis website, http://ir.prologis.com, in the "Annual & Supplemental Reports" section.
Earnings Webcast and Conference Call
Interested parties are encouraged to access the live webcast by clicking the microphone icon located near the top of the opening page on the ProLogis website at http://ir.prologis.com. Interested parties can also participate via conference call by dialing (866) 305-2304 domestically or (660) 422-4873 internationally.
Replay Information
A replay of the conference call will be available after 1:00 p.m. Eastern Time on Thursday, April 22, 2010. The replay will be available until midnight Eastern Time on Thursday, May 6, 2010, and can be accessed by dialing (800) 642-1687 domestically or (706) 645-9291 internationally and entering the passcode 64192810. A transcript of the call and the webcast replay will be available in the "Quarterly Results" section on the ProLogis website.
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,400 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com.
Follow ProLogis on Twitter: http://twitter.com/ProLogis
SOURCE ProLogis
The Hartford Completes Capital Raise; Plans to Return Treasury Investment
Date : 03/23/2010 @ 10:30AM
Source : Business Wire
Stock : The Hartford Financial Services Group, Inc. (HIG)
http://ih.advfn.com/p.php?pid=nmona&cb=1269354943&article=42086337&symbol=NY^HIG
The Hartford Completes Capital Raise; Plans to Return Treasury Investment
The Hartford Financial Services Group, Inc. (NYSE: HIG) today announced that it has completed its previously announced equity and debt offerings as part of its plan to fully repurchase the $3.4 billion of The Hartford’s preferred shares issued to the U.S. Treasury under Treasury’s Capital Purchase Program (CPP).
“We were pleased with the execution of the capital raise,” said Liam E. McGee, The Hartford’s Chairman, President and Chief Executive Officer. “There was a high level of investor interest in our offerings and pricing was favorable, reflecting confidence in The Hartford’s future. With the funds secured, we are moving forward with our plans to repurchase Treasury’s preferred shares.”
Investors purchased 59.59 million shares of The Hartford’s common stock; 23 million depositary shares, each representing a 1/40th interest in a share of The Hartford’s 7.25% Mandatory Convertible Preferred Stock, Series F; and $1.1 billion of its senior notes, consisting of $300 million of its 4.00% Senior Notes due 2015, $500 million of its 5.50% Senior Notes due 2020 and $300 million of its 6.625% Senior Notes due 2040. The number of securities sold in the common stock and depositary shares offerings included 7.3 million shares of common stock and 3 million depositary shares issued to the underwriters of those offerings upon the exercise of their respective options to purchase additional securities.
The Hartford plans, subject to approval, to use $425 million of the net proceeds from the debt offering, together with the net proceeds of its common stock and depositary shares offerings and available funds, to repurchase the $3.4 billion of preferred shares issued to the U.S. Treasury under Treasury’s Capital Purchase Program. Remaining proceeds from the senior notes offering are planned to be used to pre-fund the maturity of The Hartford’s senior debt maturing in 2010 and 2011.
About The Offering
Goldman, Sachs & Co. and J.P. Morgan Securities Inc. acted as joint bookrunning managers for the offering of common stock and depositary shares.
Goldman, Sachs & Co., J.P. Morgan Securities Inc., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC acted as joint bookrunning managers for the offering of senior notes.
About The Hartford
Celebrating nearly 200 years, The Hartford (NYSE: HIG) is an insurance-based financial services company that serves households, businesses and employees by helping to protect their assets and income from risks, and by managing wealth and retirement needs. A Fortune 500 company, The Hartford is recognized widely for its service expertise and as one of the world's most ethical companies.
HIG-F
This news release shall not constitute an offer to sell or a solicitation to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. These offerings were made only by means of a prospectus and related prospectus supplement, which may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, NY 10004, telephone: 866-471-2526, fax: 212-902-9316, email: Prospectus-ny@ny.email.gs.com or by contacting J.P. Morgan Securities Inc. via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204.
Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Annual Report for fiscal year 2009 on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.
Events & Tradeshows
AACR 101st Annual Meeting 2010: Methods Workshops
Date: April 17, 2010
Location: Washington, DC
Next-Generation Sequencing: Data Analysis and Applications Workshop
Saturday, April 17
3:15 p.m.-5:15 p.m.
Presentation:
"An integrative genomics view of cancer biology using helicos single-molecule sequencing", Patrice M. Milos
http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/program/methods-workshops.aspx
Events & Tradeshows
AACR 101st Annual Meeting 2010: Methods Workshops
Date: April 17, 2010
Location: Washington, DC
Next-Generation Sequencing: Data Analysis and Applications Workshop
Saturday, April 17
3:15 p.m.-5:15 p.m.
Presentation:
"An integrative genomics view of cancer biology using helicos single-molecule sequencing", Patrice M. Milos
http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/program/methods-workshops.aspx
Helicos BioSciences Featured at Advances in Genome Biology and Technology Meeting
Unique Capabilities of Single Molecule Sequencing and the Helicos® Genetic Analysis System Showcased
Press Release Source: Helicos BioSciences Corporation
On Tuesday February 23, 2010, 7:00 am EST
http://finance.yahoo.com/news/Helicos-BioSciences-Featured-bw-1953215962.html?x=0&.v=1
Helicos BioSciences Featured at Advances in Genome Biology and Technology Meeting
Unique Capabilities of Single Molecule Sequencing and the Helicos® Genetic Analysis System Showcased
Press Release Source: Helicos BioSciences Corporation
On Tuesday February 23, 2010, 7:00 am EST
http://finance.yahoo.com/news/Helicos-BioSciences-Featured-bw-1953215962.html?x=0&.v=1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences (NASDAQ:HLCS - News) and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010. The presentations demonstrate the unique attributes of single molecule sequencing available for customers using the Helicos® Genetic Analysis System, and highlight the suitability of the technology for answering difficult and previously intractable questions in biology and medicine.
Dr. Timothy Triche, MD, PhD, University of Southern California on behalf of the Children’s Oncology Group will discuss recent collaborative studies undertaken with Helicos in a talk entitled “Unraveling the Complexity of Primary and Metastatic Ewing’s Sarcoma Using Helicos Single Molecule Sequencing”. Using a Helicos® Genetic Analysis System, the group performed a comprehensive and quantitative survey of a cancer patient's genome and transcriptome to identify changes responsible for tumor metastasis and drug resistance.
In a talk entitled “A True Unbiased View of Genome Biology: Helicos Single Molecule Sequencing” Patrice Milos, PhD, Vice President and Chief Scientific Officer, of Helicos will present the technology’s unique ability to perform Direct RNA Sequencing and Direct Chromatin Immunoprecipitation Sequencing (ChIP-Seq), providing unbiased quantitation and sequence information. The unparalleled quantitative accuracy of Helicos' direct measurement will be demonstrated relative to 2nd Generation, amplification-based technologies.
In addition, John Thompson, PhD, Helicos’s Senior Director of Genomic Sciences, will give a poster presentation entitled “Single Molecule Sequencing of DNA Invisible to Other Technologies” describing Helicos' unique ability to sequence DNA from samples other technologies can't. These include samples that are highly degraded, contaminated or of very ancient origin.
The Helicos® Genetic Analysis System is the world's first and only commercially available technology capable of True Single Molecule Sequencing (tSMS)TM. Unlike amplification-based technologies, the Helicos approach is free from the biases and artifacts associated with amplification, and provides a direct view of biological samples, enabling applications that can revolutionize biology, diagnostics and medicine.
About Helicos BioSciences:
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS(TM), technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of two $1,000 genome grants and committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800. For more information, please visit www.helicosbio.com.
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the prospective value of the unique attributes of single molecule sequencing as discussed in this press release and the presentations at the AGBT meeting, and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete and/or scale the manufacturing and commercialization process for the Helicos® Genetic Analysis System; our history of operating losses and ability to achieve profitability; our ability to sustain and scale our manufacturing capabilities; the research and development spending levels of academic, clinical and governmental research institutions and pharmaceutical, biotechnology and agriculture companies who may purchase our Helicos® Genetic Analysis System; our reliance on third-party suppliers; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; the length of our sales and implementation cycles; our dependence on large contracts for the sale and implementation of our Helicos® Genetic Analysis System; failure of our technology and products; our ability to maintain customer relationships and contracts; ethical, legal and social concerns surrounding the use of genetic information; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our growth while operating with limited resources; our ability to control our operating expenses; general economic and business conditions; our ability to obtain capital when desired on favorable terms; and the volatility of the market price of our common stock. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.
Contact:
Investor Relations:
Helicos BioSciences Corporation
Susan Shepard, 617-264-1850
...holding but will sell soon my "free shares" of this!
IMO - no hopes left
EMCORE Connects Cables Demonstrate Excellent Field Reliability in High-Performance Computing Applications
Date : 03/22/2010 @ 11:38AM
Source : MarketWire
Stock : EMCORE (EMKR)
http://ih.advfn.com/p.php?pid=nmona&article=42069451&symbol=EMKR
EMCORE Corporation (NASDAQ: EMKR), a leading provider of compound semiconductor-based components and subsystems for the fiber optic and solar power markets, today announced the reliability results of its fielded 20Gb/s active optical cables.
High performance computing systems require guaranteed reliable, high bandwidth, low-latency communication paths to connect up to thousands of processing nodes. Traditionally, these pathways are implemented using copper cables. However, due to their bulk, weight and limited transmission distance, copper cables often constrain the physical size and performance of these server clusters. EMCORE Connects Cables? active optical cables, on the other hand, are a proven solution. They are compact, lightweight, and allow for greater reach between processing nodes than traditional copper cables.
According to a recent report by LightCounting, sales of active optical cables during the last three years were more than 150,000 units, with EMCORE shipping the majority of that volume. The reliability of EMCORE Connects Cables over that time period is better than 5 FITs, or 5 failures in one billion hours of device operation. This reliability performance demonstrates the suitability of 850-nm VCSEL (vertical cavity surface emitting laser) array technology and multimode optical fiber for high performance data computing applications.
Chris Wiggins, Director of EMCORE's Enterprise Business Group says, "EMCORE is the field-proven market leader in high quality and reliable active optical cable products." He added, "Our current generation of 40Gb/s active optical cable is based on the same technology and we expect the same high reliability performance of these newer products. We are committed to providing customers with the highest performance, quality and reliable optical interconnect products."
EMCORE Connects Cables are bidirectional communications links converting four lanes of electrical signals into optical ones by modulating four monolithically-integrated VCSELs operating at 850nm wavelengths. The optical signals are carried by thin multimode optical fiber strands to the opposite end where they are converted back to electrical signals by a four-channel photodetector array. The use of high bandwidth, low loss optical fibers allow the information to be transmitted at distances of more than ten times greater than that of copper cables.
Presently, the EMCORE Connects Cables product family with CX4 and QSFP interfaces is being sold in high volume for a range of applications including InfiniBand®, Ethernet, Fibre Channel and PCI applications. The cables come in lengths up to 100 meters and operate at speeds of up to 40 Gb/s. In April 2010, the company is expected to sample the next generation 150 Gb/s CXP form-factor optical cable based on the same technology platform.
For more information EMCORE will exhibiting at the Optical Fiber Communication Conference and Exposition (OFC) in San Diego on March 23-25, 2010, booth 2134 or please visit www.emcore.com.
About EMCORE:
EMCORE Corporation is a leading provider of compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite and terrestrial solar power markets. EMCORE's Fiber Optics unit offers optical components, subsystems and systems that enable the transmission of video, voice and data over high-capacity fiber optic cables for high-speed data and telecommunications, cable television (CATV) and fiber-to-the-premises (FTTP) networks. EMCORE's Solar Power unit provides solar products for satellite and terrestrial applications. For satellite applications, EMCORE offers high-efficiency compound semiconductor-based gallium arsenide (GaAs) solar cells, covered interconnect cells and fully integrated solar panels. For terrestrial applications, EMCORE offers concentrating photovoltaic (CPV) systems for utility scale solar applications as well as offering its high-efficiency GaAs solar cells and CPV components for use in solar power concentrator systems. For specific information about our company, our products or the markets we serve, please visit our website at www.emcore.com.
Safe Harbor:
Statements in this press release that are not historical facts, and the assumptions underlying such statements, constitute "forward-looking statements" and assumptions underlying "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and involve a number of risks and uncertainties, including (a) the failure of the products mentioned (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, and (iii) to be successful under field conditions, (b) the failure of the products to be selected by prospective customers for large-scale deployment and (c) the ability of the Company's customers to achieve their own business goals and objectives. Readers should also review the risk factors set forth in EMCORE's Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and EMCORE's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2009. These forward-looking statements are made as of the date hereof, and EMCORE does not assume any obligation to update these statements.
EMCORE Connects Cables is a trademark of EMCORE Corporation. All other brand and product names mentioned herein are the property of their respective companies.
Cell Therapeutics' FDA Panel: Live Blog
http://www.thestreet.com/story/10707111/1/cell-therapeutics-fda-panel-live-blog.html
BLOCKBUSTER On Demand(R) to be Available on the Latest Samsung Connected HDTVs, Blu-ray Players and Home Theater Systems
Date : 03/22/2010 @ 6:58AM
Source : PR Newswire
Stock : Blockbuster (BBI)
http://ih.advfn.com/p.php?pid=nmona&article=42063648&symbol=BBI
BLOCKBUSTER On Demand(R) to be Available on the Latest Samsung Connected HDTVs, Blu-ray Players and Home Theater Systems
Get the hottest new releases on the hottest new devices
PR Newswire
DALLAS, March 22
DALLAS, March 22 /PRNewswire-FirstCall/ --
Blockbuster Inc. (NYSE: BBI, BBI.B) announced that BLOCKBUSTER On Demand® will reach millions more homes across America through the latest models of Samsung connected HDTVs, Blu-ray players and Blu-ray integrated home theater systems. Consumers now have even more ways to enjoy the hottest new releases from BLOCKBUSTER.
BLOCKBUSTER On Demand is part of the newly-launched Samsung Apps, the first HDTV-based application store where users can download applications from select 2010 Samsung HDTVs, Blu-ray players and home theater systems via the upgraded Internet@TV – Content Service.
"BLOCKBUSTER On Demand brings you instant access to the latest movies, with new releases available the same day as DVD/Blu-ray," said Bruce Anderson, BLOCKBUSTER On Demand's senior vice president and general manager. "We're bringing our customers the movies they want, when and where they want them."
Customers may select from thousands of movies including the hottest new releases and classic movies, directly on their TV set and with no monthly fee. This allows for a more personalized and easy to use in-home movie watching experience. Powered by Sonic's Roxio CinemaNow™ technology, BLOCKBUSTER On Demand offers a seamless experience across Samsung's entire line of Internet@TV products.
About Blockbuster Inc.
Blockbuster Inc. is a leading global provider of rental and retail movie and game entertainment. The company provides customers with convenient access to media entertainment anywhere, any way they want it – whether in-store, by-mail, through vending kiosks or digitally to their homes and mobile devices. With a highly recognized brand and a library of more than 125,000 movie and game titles, Blockbuster leverages its multichannel presence to serve nearly 47 million global customers annually. The company may be accessed worldwide at www.blockbuster.com.
SOURCE Blockbuster Inc.
CTIC halted...
http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts
T1 ~ Halt - News Pending
(Trading is halted pending the release of material news.)
http://www.nasdaqtrader.com/Trader.aspx?id=TradeHaltCodes
FDA Panel Review Alert : Cell Therapeutics, ChemGenex Pharma
3/21/2010 9:27 AM ET
http://www.rttnews.com/ArticleView.aspx?Id=1246433
EMCORE Corporation Announces Expansion of ClearLightTM Tunable Laser Technology Platform With New micro-ITLA
Mar 19, 2010 08:25 ET
http://www.marketwire.com/press-release/EMCORE-Corporation-Announces-Expansion-ClearLight-Tunable-Laser-Technology-Platform-NASDAQ-emkr-1134633.htm
ALBUQUERQUE, NM--(Marketwire - March 19, 2010) - EMCORE Corporation (NASDAQ: EMKR), a leading provider of compound semiconductor-based components and subsystems for the fiber optic and solar power markets, today announced the expansion of its Telecom DWDM product portfolio empowered by the ClearLight™ proprietary tunable external-cavity laser (ECL) technology platform, with the introduction of the new micro-ITLA (Integrable Tunable Laser Assembly).
EMCORE's micro-ITLA is specifically designed to meet the needs of 40 and 100 Gb/s (gigabits per second) line-cards and transponders. Its features include narrow linewidth, low noise, frequency fine tune and high output power, while providing the full functionality of the ITLA multi-source agreement (MSA) in a quarter-size form factor and with half the power consumption. This next step in product density is made possible by EMCORE's ClearLight™ technology which builds upon several generations of EMCORE's industry-leading tunable products, having over 500 million total field hours. Heino Bukkems, Product Line Manager for the micro-ITLA, stated, "The EMCORE ECL laser has always been the device of choice for next-generation 40 and 100 Gb/s systems. The size-reduced micro-ITLA enables the emergence of smaller 40 and 100 Gb/s transponders. Our experienced engineering team and a deep understanding of our core technology have made this highly differentiated product possible."
The new micro-ITLA is the third product empowered by EMCORE's ClearLight™ technology, joining the tunable TOSA and tunable XFP products announced last year. Rob Stone, Marketing Director of EMCORE's Fiber Optics Division, stated, "The modularity and flexibility of our technology platform enables a wide array of product variants and next generation enhancements simply through the substitution of a few standard components. We can then integrate our ClearLight™ optical engines at different levels, all the way from TOSA and laser assemblies, to transceivers and transponders to meet the specific needs of our customers."
EMCORE will be conducting demonstrations of the new micro-ITLA at the Optical Fiber Communication Conference and Exposition (OFC) in San Diego on March 23-25 2010.
For more information, visit EMCORE at www.emcore.com.
About EMCORE
EMCORE Corporation is a leading provider of compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite and terrestrial solar power markets. EMCORE's Fiber Optics segment offers optical components, subsystems and systems that enable the transmission of video, voice and data over high-capacity fiber optic cables for high-speed data and telecommunications, cable television (CATV) and fiber-to-the-premises (FTTP) networks. EMCORE's Solar Power segment provides solar products for satellite and terrestrial applications. For satellite applications, EMCORE offers high- efficiency compound semiconductor-based gallium arsenide (GaAs) solar cells, covered interconnect cells and fully integrated solar panels. For terrestrial applications, EMCORE offers concentrating photovoltaic (CPV) systems for utility scale solar applications as well as offering its high-efficiency GaAs solar cells and CPV components for use in solar power concentrator systems. For specific information about our company, our products or the markets we serve, please visit our website at http://www.emcore.com.
Safe Harbor:
Statements in this press release that are not historical facts, and the assumptions underlying such statements, constitute "forward- looking statements" and assumptions underlying "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and involve a number of risks and uncertainties, including (a) the failure of the products mentioned (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, and (iii) to be successful under field conditions, (b) the failure of the products to be selected by prospective customers for large-scale deployment and (c) the ability of the Company's customers to achieve their own business goals and objectives. Readers should also review the risk factors set forth in EMCORE's Annual Report on Form 10-K for the fiscal year ended September 30, 2009. These forward-looking statements are made as of the date hereof, and EMCORE does not assume any obligation to update these statements.
EMCORE Releases High-Power, Ultra-Low RIN DWDM Laser Modules
Date : 03/18/2010 @ 7:44PM
Source : MarketWire
Stock : EMCORE (EMKR)
http://ih.advfn.com/p.php?pid=nmona&article=42035949&symbol=EMKR
EMCORE Corporation (NASDAQ: EMKR), a leading provider of compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite and terrestrial solar power markets, announced the introduction and immediate availability of a new line of high-power, > 100 milliwatt (mW), continuous-wave (CW) source laser modules for 1550-nm range DWDM applications.
The DWDM 100-mW high-power CW laser module, available in all ITU grid wavelengths, offers solutions for growing demands of high optical power in DWDM, CATV networks, and free space optics applications. The laser module is DC-coupled with a built-in TEC, thermistor, and monitor photodiode. The device is mounted in a 14-pin, OC-48 pinout compatible butterfly package with the optical isolator mounted on the TEC. It also incorporates an innovative, high efficiency coupling scheme to deliver more than 100-mW CW optical power at a low bias current. Features of these laser modules, model number 1782, include:
Operating temperature ranges from -20 degreesC to +65 degreesC
Ultra low RIN (relative intensity noise) is typically less than -170 dB/Hz
Optical power output is greater than 100 mW
Maximum laser bias current is 450 mA
"The ultra low RIN and high optical power makes this product family an excellent choice to design into externally modulated transmitters that require high optical power or dual optical power outputs for RFoG and FTTx networks," said Vu Tran, Optical Component Product Line Manager for EMCORE Broadband. The laser modules are immediately available. Please visit our booth at the Optical Fiber Communication Conference and Exposition (OFC) in San Diego on March 23-25, 2010, for more information.
ABOUT EMCORE
EMCORE Corporation is a leading provider of compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite and terrestrial solar power markets. EMCORE's Fiber Optics segment offers optical components, subsystems and systems that enable the transmission of video, voice and data over high-capacity fiber optic cables for high-speed data and telecommunications, cable television (CATV) and fiber-to-the-premises (FTTP) networks. EMCORE's Solar Photovoltaics segment provides solar products for satellite and terrestrial applications. For space and satellite applications, EMCORE offers high-efficiency compound semiconductor-based gallium arsenide (GaAs) solar cells, covered interconnect cells and fully integrated solar panels. For terrestrial applications, EMCORE offers concentrating photovoltaic (CPV) systems for utility scale solar applications as well as offering its high-efficiency GaAs solar cells and CPV components for use in solar power concentrator systems. For specific information about our company, our products or the markets we serve, please visit our website at www.emcore.com.
Safe Harbor:
Statements in this press release that are not historical facts, and the assumptions underlying such statements, constitute "forward-looking statements" and assumptions underlying "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and involve a number of risks and uncertainties, including (a) the failure of the products mentioned (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, and (iii) to be successful under field conditions, (b) the failure of the products to be selected by prospective customers for large-scale deployment and (c) the ability of the Company's customers to achieve their own business goals and objectives. Readers should also review the risk factors set forth in EMCORE's Annual Report on Form 10-K for the fiscal year ended September 30, 2009. These forward-looking statements are made as of the date hereof, and EMCORE does not assume any obligation to update these statements.
The Hartford Prices Common and Depositary Share Offerings
18.03.2010 00:41
http://www.finanznachrichten.de/nachrichten-2010-03/16405928-the-hartford-prices-common-and-depositary-share-offerings-004.htm
The Hartford Financial Services Group, Inc. (NYSE: HIG) today announced that it has priced an offering of 52.253 million shares of its common stock at a price of $27.75 per share. In addition, The Hartford announced it has priced a concurrent offering of 20 million depositary shares, each representing a 1/40th interest in The Hartford's 7.25% Mandatory Convertible Preferred Stock, Series F at a price of $25 per depositary share.
The underwriters for the respective offerings will have a 30-day option to purchase up to an additional 15 percent of the original issuance amount, or approximately 8 million shares, of common stock and up to an additional 3 million depositary shares, in each case at the public offering price less the underwriting discount. The closing is expected to occur on or about March 22, 2010.
The Hartford plans to use the net proceeds of the offerings, together with proceeds from a planned debt offering and available funds to repurchase in full the $3.4 billion of The Hartford's preferred shares issued to the U.S. Treasury Department under Treasury's Capital Purchase Program once it has received approval to do so. Following the repurchase, the U.S. Treasury Department will continue to hold a warrant to purchase approximately 52 million shares of The Hartford's common stock at an exercise price of $9.79 per share, subject to adjustment. The Hartford does not intend to repurchase the warrant.
About The Offering
Goldman, Sachs&Co. and J.P. Morgan Securities Inc. are acting as joint bookrunning managers for the offerings of common stock and depositary shares, each representing a 1/40th interest in a share of 7.25% Mandatory Convertible Preferred Stock, Series F.
The proposed offerings will be made only by means of a prospectus and related prospectus supplement, which may be obtained by visiting the SEC's website at www.sec.gov or by contacting Goldman, Sachs&Co., Attention: Prospectus Department, 85 Broad Street, New York, NY 10004, telephone: 866-471-2526, fax: 212-902-9316, email: Prospectus-ny@ny.email.gs.com or by contacting J.P. Morgan Securities Inc. via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,1-866-803-9204.
About The Hartford
Celebrating nearly 200 years, The Hartford (NYSE: HIG) is an insurance-based financial services company that serves households, businesses and employees by helping to protect their assets and income from risks, and by managing wealth and retirement needs. A Fortune 500 company, The Hartford is recognized widely for its service expertise and as one of the world's most ethical companies.
HIG-F
This news release shall not constitute an offer to sell or a solicitation to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Annual Report for fiscal year 2009 on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.
Contacts:
The Hartford Financial Services Group, Inc.
Media Contact:
Shannon Lapierre, 860-547-5624
Shannon.Lapierre@thehartford.com
or
Investor Contact:
Rick Costello, 860-547-8480
Richard.Costello@thehartford.com
or
JR Reilly, 860-547-9140
JR.Reilly@thehartford.com
© 2010 Business Wire
NewCardio Signs Master Services Agreement (MSA) with U.S.-Based Contract Research Organization (CRO) for QTinno
Date : 03/18/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=42023814&symbol=NWCI
NewCardio Signs Master Services Agreement (MSA) with U.S.-Based Contract Research Organization (CRO) for QTinno
QTinno Enables CRO to Add Electrocardiogram (ECG) Core Lab Services to Extend its Scope of Services
PR Newswire
SANTA CLARA, Calif., March 18
SANTA CLARA, Calif., March 18 /PRNewswire-FirstCall/ --
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
In addition, the CRO has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, in order to accelerate its readiness for delivering ECG core lab services to its sponsor customers. Revenue from the professional services agreement is expected to be recognized during March 2010 with the implementation scheduled to be complete within the next 4-6 weeks. NewCardio has recognized its first operating revenues as a result of this order.
"This announcement is further evidence of the growing adoption of QTinno, by innovative clinical trial service providers, looking to deliver quality cardiac safety analysis with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," said Vincent Renz, NewCardio President and Chief Operating Officer. "One of our target customers is clinical trial service providers, looking to deploy our proven technology to expand services and grow market opportunities. For this CRO, adding to its available scope of services, by utilizing QTinno, accomplished these two important goals."
NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead ECG. NewCardio's lead product is QTinno, a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno, software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
Top 10 Oil/Gas Production Stocks with Highest Upside: SNG, KAZ, GMET, BQI, CFW, FUEL, SYMX, WRES, CXPO, GMXR (Mar 11, 2010)
Thursday, March 11, 2010
http://www.cnanalyst.com/2010/03/top-10-oilgas-production-stocks-with-highest-upside-sng-kaz-gmet-bqi-cfw-fuel-symx-wres-cxpo-gmxr-ma.html
Below are the top 10 Oil/Gas Production stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
Canadian Superior Energy Inc. (USA) (AMEX:SNG) has the 1st highest upside potential in this segment of the market. Its upside is 1081.8%. Its consensus target price is $7.00 based on the average of all estimates. BMB Munai Inc. (AMEX:KAZ) has the 2nd highest upside potential in this segment of the market. Its upside is 462.3%. Its consensus target price is $5.96 based on the average of all estimates. GeoMet, Inc. (NASDAQ:GMET) has the 3rd highest upside potential in this segment of the market. Its upside is 312.4%. Its consensus target price is $4.00 based on the average of all estimates. Oilsands Quest Inc. (AMEX:BQI) has the 4th highest upside potential in this segment of the market. Its upside is 301.6%. Its consensus target price is $3.20 based on the average of all estimates. Cano Petroleum, Inc. (AMEX:CFW) has the 5th highest upside potential in this segment of the market. Its upside is 208.0%. Its consensus target price is $2.87 based on the average of all estimates.
SMF Energy Corporations (NASDAQ:FUEL) has the 6th highest upside potential in this segment of the market. Its upside is 185.7%. Its consensus target price is $4.00 based on the average of all estimates. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) has the 7th highest upside potential in this segment of the market. Its upside is 98.0%. Its consensus target price is $2.00 based on the average of all estimates. Warren Resources, Inc. (NASDAQ:WRES) has the 8th highest upside potential in this segment of the market. Its upside is 93.1%. Its consensus target price is $5.00 based on the average of all estimates. Crimson Exploration Inc. (NASDAQ:CXPO) has the 9th highest upside potential in this segment of the market. Its upside is 84.4%. Its consensus target price is $6.25 based on the average of all estimates. GMX Resources Inc. (NYSE:GMXR) has the 10th highest upside potential in this segment of the market. Its upside is 80.3%. Its consensus target price is $17.83 based on the average of all estimates.
Top 10 Oil/Gas Production Stocks with Highest Upside: SNG, KAZ, GMET, BQI, CFW, FUEL, SYMX, WRES, CXPO, GMXR (Mar 11, 2010)
Thursday, March 11, 2010
http://www.cnanalyst.com/2010/03/top-10-oilgas-production-stocks-with-highest-upside-sng-kaz-gmet-bqi-cfw-fuel-symx-wres-cxpo-gmxr-ma.html
Below are the top 10 Oil/Gas Production stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
Canadian Superior Energy Inc. (USA) (AMEX:SNG) has the 1st highest upside potential in this segment of the market. Its upside is 1081.8%. Its consensus target price is $7.00 based on the average of all estimates. BMB Munai Inc. (AMEX:KAZ) has the 2nd highest upside potential in this segment of the market. Its upside is 462.3%. Its consensus target price is $5.96 based on the average of all estimates. GeoMet, Inc. (NASDAQ:GMET) has the 3rd highest upside potential in this segment of the market. Its upside is 312.4%. Its consensus target price is $4.00 based on the average of all estimates. Oilsands Quest Inc. (AMEX:BQI) has the 4th highest upside potential in this segment of the market. Its upside is 301.6%. Its consensus target price is $3.20 based on the average of all estimates. Cano Petroleum, Inc. (AMEX:CFW) has the 5th highest upside potential in this segment of the market. Its upside is 208.0%. Its consensus target price is $2.87 based on the average of all estimates.
SMF Energy Corporations (NASDAQ:FUEL) has the 6th highest upside potential in this segment of the market. Its upside is 185.7%. Its consensus target price is $4.00 based on the average of all estimates. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) has the 7th highest upside potential in this segment of the market. Its upside is 98.0%. Its consensus target price is $2.00 based on the average of all estimates. Warren Resources, Inc. (NASDAQ:WRES) has the 8th highest upside potential in this segment of the market. Its upside is 93.1%. Its consensus target price is $5.00 based on the average of all estimates. Crimson Exploration Inc. (NASDAQ:CXPO) has the 9th highest upside potential in this segment of the market. Its upside is 84.4%. Its consensus target price is $6.25 based on the average of all estimates. GMX Resources Inc. (NYSE:GMXR) has the 10th highest upside potential in this segment of the market. Its upside is 80.3%. Its consensus target price is $17.83 based on the average of all estimates.
...
SNWT is back and firing on all cylinders
Buckle-Up Folks! We're Going Off-Roading!
Good Morning Trader!
How's this for an action-packed pick...
San West, Inc. (SNWT)
SNWT is a retailer of premier off-road vehicles (dune buggies, sand rails and ATV's) and a leading supplier of aftermarket parts and accessories.
And, it's also a highly successful off-road vehicle (ORV) repair and maintenance center.
Plus, SNWT is aggressively expanding its market share through strategic acquisitions, as well as experiencing its own rapid internal growth.
in fact, I just got my hands on one of their souped-up, adrenaline machines and I think I am in love again. Even if you decide the stock is not for you, you need to
Recent SNWT acquisitions, partnerships and developments...
* Buggy World:—a retailer of off-road buggies, buggy parts and accessories is now a SNWT wholly-owned subsidiary
* Letz Go Racing Off-Road Center:—a developer of aftermarket, high-performance accessories for off-road all-terrain vehicles such as Go Karts is also a SNWT wholly-owned subsidiary
* CountyImports.com:—owns two successful e-commerce Web sites targeted at the ORV industry, another SNWT wholly-owned subsidiary
* TrophyKart: SNWT became the exclusive dealer of this high-profile off-road brand in San Diego County
* Fox Racing, Joyner, and Thor: SNWT acquired non-exclusive sales & marketing rights for their off-road products
* ScootSpeedShop.com:—an e-commerce website showcasing high-performance parts for on-road Scooters and off-road recreational vehicles (ORVs), another SNWT owned property
And the icing on the cake...
SNWT recently announced revenue guidance for 2010 of between $6 MILLION and $8 MILLION! (click here to see the announcement: http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=SNWT.OB×tamp=20091229133000 )
If SNWT can hit those numbers that would mean their sales could triple or even quadruple the revenue they did in 2009!
And now this!
SNWT announced they have secured financing in the amount of $10 MILLION an investment banker that works with promising, growth companies.
SNWT plans to use this money to accelerate its already impressive growth and implement additional marketing initiatives.
And let's not forget SNWT's chart!
* The stock has pulled back nearly 50% from its recent intermediate-term high reached in February to its recent intermediate-term low.
* Volume is expanding during rallies and contracting during pullbacks. This shows healthy signs of accumulation with only light profit-taking (no panic-selling) during the subsequent pullback.
* While the MACD is, admittedly, pointing down, I think it may be poised to reverse based on the contraction of downside momentum (as illustrated on the MACD histogram.)
* The stochastics are deeply oversold suggesting the stock has pulled back “too far and too fast” (relative to its past pullbacks.). It also suggests a tradable rally could ensue at anytime.
Keep in mind...
We've covered SNWT before!
SNWT has come a long way since I first shared it with Beacon members.
And, once again, I like what I'm seeing -- but this time we get to see the stock at half-price!
I think they have a real strong value proposition to attract both investors and active traders.
So... complete your Due Diligence and get ready to trade SNWT.
Happy Trading!
John Baskin, CMT
Chief Market Analyst
Beacon Equity Group
BeaconEquity.com
4828 S. Broadway #182
Tyler, Texas 75703
US
ALERT - San West Inc. ( SNWT )
Mar 04, 2010:
San West Inc. Bolsters Online Presence With Website Enhancements and Paid Advertising Overhaul
Recent Upgrades Make CountyImports.com a Leader in "Natural Web Traffic"
http://www.marketwire.com/press-release/San-West-Inc-Bolsters-Online-Presence-With-Website-Enhancements-Paid-Advertising-Overhaul-1126447.htm
Mar 10, 2010:
San West Inc. and CountyImports.com Reduce Paid Advertising Costs by 37%; Become Leaders in "Natural" Web Traffic
Keyword Marketing Overhaul Campaign Improves Site Efficiency and Search Engine Optimization Success Rate
http://www.marketwire.com/press-release/San-West-Inc-CountyImportscom-Reduce-Paid-Advertising-Costs-37-Become-Leaders-Natural-1129451.htm
Mar 11, 2010:
San West and CountyImports.com Announce 23% Sales Increase for Motorized Scooters
Average Sale Price for Scooters Rises 24.5% Over 2009 Figures
http://www.marketwire.com/press-release/San-West-and-CountyImportscom-Announce-23-Sales-Increase-for-Motorized-Scooters-1130136.htm
AN DIEGO, CA--(Marketwire - March 11, 2010) - San West Inc. (OTCBB: SNWT) an emerging leader in the design, manufacturing, sales and repair of off-road buggies, announced today that motorized scooter sales generated by its partner website, www.CountyImports.com, have increased approximately 23% for the first two months of 2010 compared to the same period last year.
Management expects this segment of its business to continue to grow substantially as the Spring/Summer ORV season progresses. The Company also announced that the average sale price for scooters sold by www.CountyImports.com is up 24.5% compared to 2009 figures as consumers select higher-end scooters and those with additional features.
"Warmer Spring weather and an improving economy appears to be driving increased sales of our off road vehicles, most notably motorized scooters," commented Jesse Gonzalez, president of CountyImports.com. "Not only are scooter sales growing considerably on a unit basis, but customers are spending more on each vehicle, part and accessory than ever before. This trend provides us with increasing optimism about what the Spring/Summer season holds. It's also a strong indicator that consumers have finally recovered from the recent economic downturn and are ready to enjoy hobbies and outdoor activities."
Mr. Gonzalez added, "Due the perfect storm of positive trends currently impacting our business, we expect to log our largest historical sales increase for motorized scooters over the next 30 days. ORV season is shifting into high gear and we are receiving extremely positive initial feedback for our new product releases, which we plan to announce in the coming weeks. In addition, continued improvements to our website are making it more attractive and easier for consumers to find. By attracting a larger flow of highly-targeted web traffic, we've been able to increase the average order size considerably and expect this trend to continue as both off-road season and our web development campaign progress."
Frank Drechsler, President and CEO of San West Inc., added, "The overarching trend towards increased consumer spending on ORVs and related goods is driving scooter sales to record levels. We plan to continue to leverage our position as the No. 2 online ORV dealer in order to capitalize on market growth and aggressively target new opportunities that hold the potential to boost sales and help our business gain share from competitors."
San West Inc.
BUSINESS SUMMARY
San West, Inc. offers after market performance products and accessories for buggy manufacturers. It also provides buggy repair services. The company offers its products and services through its online store, as well as through a network of dealers. San West, Inc. is based in the United States.
IHUB: http://investorshub.advfn.com/boards/board.aspx?board_id=5679
YAHOO: http://finance.yahoo.com/q?s=SNWT.OB
New Medpodium Product Line
http://www.cardiumthx.com/pdf/MedPodium-Brochure.pdf
Pipeline Overview
NexMed's drug discovery and development arm, NexMed USA, has an extensive product pipeline ranging from early stage products to NDA stage products in the areas of Dermatology, Sexual Dysfunction, Pain, and potentially moving into Oncology.
Below is a listing of our product pipeline and the stage of development achieved for each compound.
http://www.nexmed.com/products.html
Pipeline Overview
Discovery Labs is developing its SRT™ platform with the intent to create a completely new therapeutic approach in the treatment of respiratory disease.
Product introduction begins with anticipated U.S. FDA approval of SURFAXIN®, followed by the potential launch of multiple line extensions involving a variety of dosage forms and novel indications of usage.
AEROSURF™, Discovery Labs' aerosolized surfactant candidate, represents a potential transformation in respiratory critical care by reducing or eliminating complications associated with mechanical ventilation.
http://www.discoverylabs.com/pipeline.html
Novavax management to meet with Global Hunter
Meetings to be held March 15-17 hosted by Global Hunter.
March 10, 2010
http://www.theflyonthewall.com/permalinks/entry.php/NVAXid1210329
Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Date : 03/10/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=41909237&symbol=KERX
NEW YORK, March 10 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr. Bentsur's presentation will take place on Tuesday March 16, 2010 at 8:00 a.m. PT (11:00 am ET).
A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of the webcast will be available following the conclusion of the live presentation.
As previously announced, the Company will also be presenting at the Cowen and Company 30th Annual Health Care Conference, taking place at The Boston Marriott Copley Place Hotel in Boston, MA. A live webcast of Mr. Bentsur's presentation, which will take place tomorrow, Thursday, March 11, 2010 at 11:05 a.m. ET, will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.
Media Contact: Lauren Fischer, Director of Investor Relations, Keryx Biopharmaceuticals, +1-212-531-5962, lfischer@keryx.com
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director of Investor Relations, KeryxBiopharmaceuticals, +1-212-531-5962, lfischer@keryx.com
Web Site: http://investors.keryx.com/
Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Date : 03/10/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=41909237&symbol=KERX
NEW YORK, March 10 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr. Bentsur's presentation will take place on Tuesday March 16, 2010 at 8:00 a.m. PT (11:00 am ET).
A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of the webcast will be available following the conclusion of the live presentation.
As previously announced, the Company will also be presenting at the Cowen and Company 30th Annual Health Care Conference, taking place at The Boston Marriott Copley Place Hotel in Boston, MA. A live webcast of Mr. Bentsur's presentation, which will take place tomorrow, Thursday, March 11, 2010 at 11:05 a.m. ET, will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.
Media Contact: Lauren Fischer, Director of Investor Relations, Keryx Biopharmaceuticals, +1-212-531-5962, lfischer@keryx.com
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director of Investor Relations, KeryxBiopharmaceuticals, +1-212-531-5962, lfischer@keryx.com
Web Site: http://investors.keryx.com/